Comparing the current results to its competitors, Pluri Inc reported Revenue decrease in the 3 quarter 2026 year on year by -60.89 %, faster than the overall decrease of Pluri Inc 's competitors by -11.18 %, recorded in the same quarter.
Pluri Inc 's Comment on Competition and Industry Peers
Ever After Foods operates in the cultivated meat and AgTech industries. In the cultivated meat market, it competes with consumer-facing companies Upside Foods, Believer Meats, and GOOD Meat, as well as business-to-business companies Gelatex, Esco Aster, Ark Biotech, and GEA. In the AgTech sector, competitors include California Cultured, Inc., Ayana Bio LLC, DSM Firmenich AG, and Givaudan International SA. Ever After Foods utilizes proprietary technology for natural cell growth. Its AgTech operations focus on cell-cultured coffee through Coffeesai and cell-cultured cacao via Kokomodo, supported by a 3D cell expansion platform developed by Pluri Biotech.
March 5, 2025
In a significant development aimed at enhancing Ukraine’s resilience against radiation emergencies, Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR), a pioneering biotechnology firm, has entered into an exclusive collaboration agreement with Hemafund Ltd. a prominent Ukrainian umbilical cord blood bank known for its specialized clinical and research facilities in cell preservation and cryostorage. This partnership, announced on March 5, 2025, marks a strategic initiative poised to bolster the country’s preparedness for catastrophic events, particularly the potential onset of Hematopoietic Acute Radiation Syndrome (H-ARS).The Collaboration Agreement lays the groundwork for a comprehensive strategy focused on the st...
May 20, 2024
Novel Medical Food Solution for the Elderly: Pluri and Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial ScaleHAIFA, Israel - In a groundbreaking partnership, leading biotechnology company Pluri Inc. has joined forces with Wilk Technologies Ltd. to develop a novel medical food solution for the elderly. Pluri, known for its innovative cell transformation technologies, will combine its cutting-edge 3D cell-expansion technology with Wilk Technologies expertise in developing cultured human breast and animal milk products. Together, they aim to create a unique and commercially viable medical food product derived from the components of breast milk.The elderly population faces u...
January 23, 2024
Step into the Future: Pluri Inc. Introduces Cell-Based Coffee to Combat the Global Coffee CrisisHAIFA, Israel, Jan. 23, 2024 - Pluri Inc., a prominent biotech company dedicated to promoting global well-being and sustainability, has recently unveiled its groundbreaking cell-based coffee production. This innovative product has the potential to revolutionize the traditional coffee industry and provide a sustainable solution to the growing global demand for high-quality coffee. With their cell-based approach, Pluri aims to address the alarming coffee crisis, ensuring mass scale production while preserving the environment.The global coffee industry has been facing numerous challenges, including climate change, de...
December 21, 2023
Pluri and Bar-Ilan University Collaborate to Develop Groundbreaking Treatment for Cocaine AddictionHAIFA, Israel - In an exciting development for the biomedical field, Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR), a renowned biotech company focused on cellular therapeutics, has recently entered into an agreement with BIRAD Research and Development Company Ltd., the commercial arm of Bar-Ilan University. This partnership aims to jointly develop Pluri s PLX cells as an innovative treatment for cocaine addiction. The agreement grants Bar-Ilan University, through BIRAD, the rights to advance and commercialize PLX cells as an anti-addiction product, while Pluri Inc. will receive a 20% revenue share from future sales.Co...
MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.
Lexeo Therapeutics Inc is a biotechnology company focused on developing advanced gene therapies for the treatment of genetic disorders. Their business model revolves around leveraging cutting-edge technology and scientific expertise to develop innovative gene therapies that address significant unmet medical needs. They aim to bring these therapies to market through strategic partnerships and collaborations with pharmaceutical companies and academic institutions.
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
Sources:
Pluri Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pluri Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
